Key Insights

Highlights

Treatment Research

2 treatments under study, led by Fxr0906 Injection

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 2 (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07889245Phase 2Not Yet RecruitingPrimary

A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.

Showing all 1 trials

Research Network

Common Treatments

  • Fxr0906 Injection1
  • Placebo1

Active Sponsors

  • Fosun Pharmaceutical Industrial Development Shenzhen Co Ltd1

Related Conditions

  • Htg With Ascvd Diagnosed Or At Increased Risk1

Activity Timeline